Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06899126 |
| Title | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer (DESTINY-Lung06) |
| Acronym | DESTINY-Lung06 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Daiichi Sankyo |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | GBR | BRA |